November 29, 2018 Life Science Tools Microscopy Product Launch

QIAGEN launches QCI Interpret bioinformatics features for use for blood cancers as well as a novel myeloid gene panel for GeneReader NGS System

Hilden, Germany, and Germantown, Maryland, November 29, 2018 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of two novel products to deliver actionable insights on a wide range of blood cancers: a new workflow for the QIAGEN Clinical Insight (QCI) Interpret bioinformatics solution for hematological malignancies, and the new QIAact Myeloid... Read more

November 28, 2018 Life Science Tools

QIAGEN extends comprehensive offering for cervical cancer screening with European launch of QIAscreen HPV PCR Test

Hilden, Germany, November 28, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAscreen HPV PCR Test, a CE-IVD marked molecular diagnostic test for the detection of 15 recognized high-risk genotypes of human papillomavirus (HPV), the virus considered to be the cause of cervical cancer. The assay includes... Read more

November 27, 2018 Chromatography Product Launch

QIAGEN releases new CLC Genomics Workbench solution designed for use in significantly more customer segments

GERMANTOWN, Maryland, and HILDEN, Germany, November 27, 2018 — QIAGEN today announced the release of a new bioinformatics analysis tool designed to bring the robustness and sophistication of the company’s industry-leading sequencing analysis solutions across research fields to biologists who do not have a primary focus on bioinformatics. The new tool works with any species... Read more

November 6, 2018 Product Launch

QIAGEN N.V. announces terms of new convertible notes

VENLO, the Netherlands, November 6, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces certain terms of the new senior unsecured cash settled convertible notes (the “Notes“). The size of the offering has been increased to $500 million aggregate principal amount. The Notes will bear interest at an annual rate of 1.00%, payable... Read more

November 6, 2018 Licensing, IP, and Legal Life Science Tools Liq. Handling & Robotics Product Launch

QIAGEN launches new QIAseq 16S Panels and UCP Multiplex PCR kit enabling unbiased microbiome profiling

Germantown, Maryland, and Hilden, Germany, June 7, 2018 – QIAGEN today announced the launch of the QIAseq 16S/ITS Panels and UCP Multiplex PCR Kit with a new generation of reagents to enable the most accurate microbial community profiling from complex microbiome samples. The new QIAseq NGS panels as well as the UCP Multiplex kit create... Read more

November 6, 2018 Product Launch

QIAGEN N.V. launches non-US offering of cash settled convertible notes combined with convertible note hedge and warrant transactions

VENLO, the Netherlands, November 6, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today its intention to launch the following series of transactions: The issue of new senior unsecured cash settled convertible notes (the “Notes“) outside the United States for $400 million aggregate principal amount; and The entry into derivative transactions to... Read more

November 5, 2018 Product Launch

QIAGEN launches new DNeasy Plant Pro Kit

Germantown, Maryland, and Hilden, Germany, November 5, 2018 – QIAGEN announced the worldwide launch of the new DNeasy Plant Pro Kit today, a system for extraction of high-quality DNA from varied plant samples with a range of features that give it a clear best in class position, such as further improved yield and effective inhibitor... Read more

October 29, 2018 Clinical Research/Diagn. Informatics & Software Life Science Tools

QIAGEN expands QIAGEN Clinical Insight software to support all major sequencing platforms and assay types

Hilden, Germany, and Germantown, Maryland, October 29, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of major enhancements to QIAGEN Clinical Insight (QCI) bioinformatics solutions to deliver expanded Sample to Insight workflows for clinical next-generation sequencing (NGS). QIAGEN introduced QCI Analyze Universal for full end-to-end workflow support of all... Read more

October 29, 2018 Atomic Spectroscopy Clinical Research/Diagn. Life Science Tools Microscopy

QIAGEN expands next-generation sequencing portfolio with oncology and immuno-oncology panels for research using GeneReader NGS System and other platforms 

Hilden, Germany, and Germantown, Maryland, October 29, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of three innovative Sample to Insight workflows for next-generation sequencing (NGS) research in oncology using QIAGEN’s GeneReader NGS System and other NGS platforms. QIAGEN is introducing the novel NGS workflows for clinical research in... Read more